NCT05737355 Effect of ANKASCIN 568-P Products Regulating Blood Lipid
| NCT ID | NCT05737355 |
| Status | Recruiting |
| Phase | — |
| Sponsor | SunWay Biotech Co., LTD. |
| Condition | Hyperlipidemias |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-04-01 |
| Primary Completion | 2025-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2023-04-01 with a primary completion date of 2025-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
Eligibility Criteria
Inclusion Criteria: * Male or Female women over the age of 20 (women of childbearing age should not be pregnant or breastfeeding during the study period). * A sane and communicative adult. * 18≦BMI≦35. * Sub-healthy people with simple dyslipidemia and those who have been judged by the doctor that they do not need to take hypolipidemic drugs for the time being, or those who insist on not taking drugs. * Screening criteria Low-density lipoprotein cholesterol (LDL-C): 130\~190 mg/dL. screening criteria and high-density lipoprotein cholesterol (HLDL-C): below 50 mg/dL. * Those without other serious diseases (cancer, heart failure, diabetes, myocardial infarction, liver cirrhosis, moderate to severe liver and kidney dysfunction, stroke, etc.). * During the experiment, the daily routine and eating habits should be maintained and not changed deliberately. Exclusion Criteria: * Triglyceride TG≧500 mg/dL. * Blood pressure value: systolic blood pressure ≧ 200 mmHg or diastolic blood pressure ≧ 140 mmHg. * Patients with moderate or severe abnormal liver and kidney function (generally referring to serum aminopyruvate converting enzyme (SGPT), serum glutamate phenylacetate transaminase (SGOT) are more than 3 times the upper limit of normal or have been diagnosed Liver cirrhosis, or glomerular filtration rate eGFR≦30 ml/min/1.73m2). * Pregnant or lactating women. * Those who take traditional Chinese medicine mainly based on red yeast rice. * Those who have undergone surgery within one month. * Those who have serious diseases such as heart, liver, kidney, and hematopoietic system, mentally ill patients who do not meet the inclusion criteria, fail to use the test product according to the regulations so that the efficacy or safety cannot be judged due to incomplete data.
Contact & Investigator
WEN-HUI FANG, Ph. D.
PRINCIPAL INVESTIGATOR
Chief of Family medicine department
Frequently Asked Questions
Who can join the NCT05737355 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Hyperlipidemias. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05737355 currently recruiting?
Yes, NCT05737355 is actively recruiting participants. Contact the research team at sean.lin@sunway.cc for enrollment information.
Where is the NCT05737355 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT05737355 clinical trial?
NCT05737355 is sponsored by SunWay Biotech Co., LTD.. The principal investigator is WEN-HUI FANG, Ph. D. at Chief of Family medicine department. The trial plans to enroll 80 participants.